Clinical applications of PET and PET/CT in pediatric malignancies

References

• Stiller CA. Aetiology and epidemiology. In: Paediatric Oncology: Clinical Practice and Controversies. Plowman PN, Pinkerton CR (Eds). Chapman and Hall Medical, London, UK (1992).
   Google Scholar
• Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975–2005, National Cancer Institute, Bethesda, MD, USA (2007).
   Google Scholar
• Kumar R, Dhanpathi H, Basu S, Rubello D, Fanti S, Alavi A. Oncologic PET tracers beyond ((18)F)FDG and the novel quantitative approaches in PET imaging. Q. J. Nucl. Med. Mol. Imaging52, 50–65 (2008).
   PubMed Web of Science ®Google Scholar
• Barai S, Bandopadhayaya GP, Julka P et al. Evaluation of Tc99m-glucoheptonate for SPECT functional imaging of medulloblastoma. J. Clin. Neurosci.12(1), 36–38 (2005).
   PubMedGoogle Scholar
• O’Tuama LA, Treves ST, Larar JN et al. Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison. J. Nucl. Med.34, 1045–1051 (1993).
   PubMedGoogle Scholar
• Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH, Doyle WK. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J. Neurosurg.69, 830–838 (1988).
   PubMed Web of Science ®Google Scholar
• Di Chiro G, Oldfield E, Wright DC et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR. Am. J. Roentgenol.150, 189–197 (1988).
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Hoffman JM, Coleman RE et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann. Neurol.29, 347–355 (1991).
   PubMed Web of Science ®Google Scholar
• Hoffman JM, Hanson MW, Friedman HS et al. FDG-PET in pediatric posterior fossa brain tumors. J. Comput. Assist. Tomogr.16, 62–68 (1992).
   PubMedGoogle Scholar
• Borgwardt L, Carstensen H, Schmiegelow K, Højgaard L. Increased FDG uptake in childhood CNS tumors is associated with tumor malignancy. Clin. Positron Imaging3, 175 (2000).
   PubMedGoogle Scholar
• Holthoff VA, Herholz K, Berthold F et al.In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer72, 1394–1403 (1993).
   PubMed Web of Science ®Google Scholar
• Gururangan S, Hwang E, Herndon JE 2nd, Fuchs H, George T, Coleman RE. (18F)fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery55, 1280–1288 (2004).
   PubMedGoogle Scholar
• Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S. Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann. Nucl. Med.19, 677–683 (2005).
   PubMedGoogle Scholar
• O’Tuama LA, Phillips PC, Strauss LC et al. Two-phase (11C)L-methionine PET in childhood brain tumors. Pediatr. Neurol.6, 163–170 (1990).
   PubMedGoogle Scholar
• Sörensen J, Savitcheva I I, Engler H, Langstrom B. Utility of PET and 11C-methionine in the paediatric brain tumors. Clin. Positron Imaging3, 157 (2000).
   PubMedGoogle Scholar
• Pirotte B, Levivier M, Morelli D et al. Positron emission tomography for the early postsurgical evaluation of pediatric brain tumors. Childs Nerv. Syst.21, 294–300 (2005).
   PubMed Web of Science ®Google Scholar
• Kaplan AM, Bandy DJ, Manwaring KH et al. Functional brain mapping using positron emission tomography scanning in preoperative neurosurgical planning for pediatric brain tumors. J. Neurosurg.91, 797–803 (1999).
   PubMed Web of Science ®Google Scholar
• Pirotte B, Goldman S, Salzberg S et al. Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr. Neurosurg.38, 146–155 (2003).
   PubMed Web of Science ®Google Scholar
• Pirotte B, Goldman S, Van Bogaert P et al. Integration of (11C)methionine-positron emission tomographic and magnetic resonance imaging for image-guided surgical resection of infiltrative low-grade brain tumors in children. Neurosurgery57(1 Suppl.), 128–139 (2005).
   PubMed Web of Science ®Google Scholar
• Pirotte B, Acerbi F, Lubansu A, Goldman S, Brotchi J, Levivier M. PET imaging in the surgical management of pediatric brain tumors. Childs Nerv. Syst.23, 739–751 (2007).
   PubMedGoogle Scholar
• Borgwardt L, Højgaard L, Carstensen H et al. Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J. Clin. Oncol.23, 3030–3037 (2005).
   PubMedGoogle Scholar
• Schifter T, Hoffman JM, Hanson MW et al. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J. Comput. Assist. Tomogr.17, 509–561 (1993).
   PubMedGoogle Scholar
• Patronas NJ, Di Chiro G, Kufta C et al. Prediction of survival in glioma patients by means of positron emission tomography. J. Neurosurg.62, 816–822 (1985).
   PubMed Web of Science ®Google Scholar
• Miller E, Metser U, Avrahami G et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J. Comput. Assist. Tomogr.30, 689–694 (2006).
   PubMed Web of Science ®Google Scholar
• Montravers F, McNamara D, Landman-Parker J et al. ((18)F)FDG in childhood lymphoma: clinical utility and impact on management. Eur. J. Nucl. Med. Mol. Imaging29, 1155–1165 (2002).
   PubMed Web of Science ®Google Scholar
• Depas G, De Barsy C, Jerusalem G et al.18F-FDG PET in children with lymphomas. Eur. J. Nucl. Med. Mol. Imaging32, 31–38 (2005).
   PubMed Web of Science ®Google Scholar
• Amthauer H, Furth C, Denecke T et al. FDG-PET in 10 children with non-Hodgkin’s lymphoma: initial experience in staging and follow-up. Klin. Padiatr.217, 327–333 (2005).
   PubMed Web of Science ®Google Scholar
• Hernandez-Pampaloni M, Takalkar A, Yu JQ, Zhuang H, Alavi A. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr. Radiol.36, 524–531 (2006).
   PubMed Web of Science ®Google Scholar
• Rhodes MM, Delbeke D, Whitlock JA et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J. Pediatr. Hematol. Oncol.28, 300–306 (2006).
   PubMed Web of Science ®Google Scholar
• Hermann S, Wormanns D, Pixberg M et al. Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin44, 1–7 (2005).
   PubMedGoogle Scholar
• Rini JN, Núñez R, Nichols K et al. Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin’s disease. Pediatr. Radiol.35, 169–178 (2005).
   PubMed Web of Science ®Google Scholar
• Meany HJ, Gidvani VK, Minniti CP. Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr. Blood Cancer48, 399–402 (2007).
   PubMedGoogle Scholar
• Mody RJ, Bui C, Hutchinson RJ, Frey KA, Shulkin BL. Comparison of (18)F Fluorodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. Leuk. Lymphoma48, 699–707 (2007).
   PubMed Web of Science ®Google Scholar
• Lopci E, Burnelli R, Ambrosini V et al. (18)F-FDG PET in pediatric lymphomas: a comparison with conventional imaging. Cancer Biother. Radiopharm. DOI:10.1089/cbr.2007.0519 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J. Pediatr. Hematol. Oncol.28, 711–714 (2006).
   PubMed Web of Science ®Google Scholar
• Furth C, Steffen IG, Amthauer H et al. Early and late therapy response assessment with (18F)fluorodeoxyglucose positron emission tomography in pediatric Hodgkin’s lymphoma: analysis of a prospective multicenter trial. J. Clin. Oncol.27(26), 4385–4391 (2009).
   PubMed Web of Science ®Google Scholar
• Furth C, Denecke T, Steffen I et al. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease. J. Pediatr. Hematol. Oncol.28, 501–512 (2006).
   PubMedGoogle Scholar
• Völker T, Denecke T, Steffen I et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J. Clin. Oncol.25, 5435–5341 (2007).
   PubMed Web of Science ®Google Scholar
• Tateishi U, Hosono A, Makimoto A et al. Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas. J. Pediatr. Hematol. Oncol.29, 608–612 (2007).
   PubMedGoogle Scholar
• Klem ML, Grewal RK, Wexler LH, Schöder H, Meyers PA, Wolden SL. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J. Pediatr. Hematol. Oncol.29, 9–14 (2007).
   PubMed Web of Science ®Google Scholar
• Peng F, Rabkin G, Muzik O. Use of 2-deoxy-2-(F-18)-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: report of a retrospective case study. Clin. Nucl. Med.31, 394–397 (2006).
   PubMedGoogle Scholar
• Arush MW, Israel O, Postovsky S et al. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr. Blood Cancer49, 901–905 (2007).
   PubMed Web of Science ®Google Scholar
• Lenzo NP, Shulkin B, Castle VP et al. FDG-PET in childhood soft tissue sarcoma. J. Nucl. Med.41(5 Suppl.), 96P (2000).
   Google Scholar
• Kumar R, Chauhan A, Vellimana AK, Chawla M. Role of PET/ PET/CT in the management of sarcomas. Expert Rev. Anticancer Ther.6(8), 1241–1250 (2006)
   PubMed Web of Science ®Google Scholar
• Shulkin BL, Mitchell DS, Ungar DR et al. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology194, 495–500 (1995).
   PubMedGoogle Scholar
• Franzius C, Sciuk J, Brinkschmidt C, Jürgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin. Nucl. Med.25, 874–881 (2000).
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer94, 3277–3284 (2002).
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Schuetze SM, Butrynski JE et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J. Clin. Oncol.23, 8828–8834 (2005).
   PubMed Web of Science ®Google Scholar
• Jadvar H, Alavi A, Mavi A, Shulkin BL. PET in pediatric diseases. Radiol. Clin. North Am.43, 135–152 (2005).
   PubMedGoogle Scholar
• Brisse H, Ollivier L, Edeline V et al. Imaging of malignant tumors of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr. Radiol.34, 595–605 (2004).
   PubMedGoogle Scholar
• Györke T, Zajic T, Lange A et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumors. Nucl. Med. Commun.27, 17–24 (2006).
   PubMed Web of Science ®Google Scholar
• Huang TL, Liu RS, Chen TH, Chen WY, Hsu HC, Hsu YC. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma. J. Chin. Med. Assoc.69, 372–376 (2006).
   PubMedGoogle Scholar
• Gurney JG, Davis S, Severson RK, Fang JY, Ross JA, Robison LL. Trends in cancer incidence among children in the US. Cancer78, 532–541 (1996).
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Maris JM. Neuroblastoma: Principles and Practice of Pediatric Oncology (4th Edition). Lippincott-Raven Publishers, PA, USA 895–937 (2001).
   Google Scholar
• Franzius C, Hermann K, Weckesser M et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system, feasibility study and comparison with 123I-MIBG SPECT/CT. J. Nucl. Med.47, 1635–1642 (2006).
   PubMed Web of Science ®Google Scholar
• Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology199, 743–750 (1996).
   PubMedGoogle Scholar
• Shulkin BL, Wieland DM, Baro ME et al. PET hydroxyephedrine imaging of neuroblastoma. J. Nucl. Med.37, 16–21 (1996).
   PubMedGoogle Scholar
• Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J. Clin. Oncol.19, 3397–3405 (2001).
   PubMed Web of Science ®Google Scholar
• Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J. Nucl. Med.50(8), 1237–1243 (2009).
   PubMed Web of Science ®Google Scholar
• Wong KK, Lan LC, Lin SC, Tam PK. The use of positron emission tomography in detecting hepatoblastoma recurrence – a cautionary tale. J. Pediatr. Surg.39, 1779–1781 (2004).
   PubMedGoogle Scholar
• Mody RJ, Pohlen JA, Malde S, Strouse PJ, Shulkin BL. FDG PET for the study of primary hepatic malignancies in children. Pediatr. Blood Cancer47, 51–55 (2006).
   PubMedGoogle Scholar
• Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-(18F)fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension38, 6–8 (2001).
   PubMed Web of Science ®Google Scholar
• Otonkoski T, Näntö-Salonen K, Seppänen M et al Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes55, 13–18 (2006).
   PubMed Web of Science ®Google Scholar
• Bombardieri E, Aktolun C, Baum RP et al. FDG-PET: procedure guidelines for tumor imaging. Eur. J. Nucl. Med. Mol. Imaging30, BP115–BPI24 (2003).
   PubMed Web of Science ®Google Scholar
• Utriainen M, Metsähonkala L, Salmi TT et al. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer95, 1376–1386 (2002).
   PubMedGoogle Scholar
• Kwon JW, Kim IO, Cheon JE et al. Paediatric brain-stem gliomas: MRI, FDG-PET and histological grading correlation. Pediatr. Radiol.36, 959–964 (2006).
   PubMed Web of Science ®Google Scholar
• Gururangan S, McLaughlin CA, Brashears J et al. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J. Neurooncol.77, 207–212 (2006).
   PubMed Web of Science ®Google Scholar